CANTINI, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 2.184
AS - Asia 768
EU - Europa 725
SA - Sud America 146
AF - Africa 84
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 3.912
Nazione #
US - Stati Uniti d'America 2.156
SG - Singapore 340
CN - Cina 191
IT - Italia 148
BR - Brasile 129
HK - Hong Kong 106
DE - Germania 103
RU - Federazione Russa 97
IE - Irlanda 88
SE - Svezia 81
VN - Vietnam 57
GB - Regno Unito 56
CI - Costa d'Avorio 54
FI - Finlandia 41
IN - India 27
FR - Francia 24
UA - Ucraina 23
CA - Canada 20
MA - Marocco 18
PL - Polonia 16
JP - Giappone 12
BE - Belgio 11
AR - Argentina 9
NL - Olanda 9
ZA - Sudafrica 9
BD - Bangladesh 8
CZ - Repubblica Ceca 7
MX - Messico 7
TR - Turchia 5
AT - Austria 4
DK - Danimarca 4
IQ - Iraq 4
KR - Corea 4
EU - Europa 3
IL - Israele 3
RO - Romania 3
UZ - Uzbekistan 3
AU - Australia 2
AZ - Azerbaigian 2
EC - Ecuador 2
EG - Egitto 2
ES - Italia 2
ID - Indonesia 2
LT - Lituania 2
PY - Paraguay 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
PH - Filippine 1
PK - Pakistan 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 3.912
Città #
Ashburn 287
Chandler 265
Singapore 245
Des Moines 241
Dallas 126
Hong Kong 106
Fairfield 96
New York 88
Boardman 83
Dublin 83
Munich 75
Abidjan 54
Ann Arbor 51
Beijing 50
Los Angeles 48
Wilmington 45
Seattle 42
Woodbridge 39
Turku 35
Jacksonville 34
Houston 33
Cambridge 32
Lawrence 31
Princeton 31
Turin 29
Buffalo 25
San Mateo 25
San Diego 24
Santa Clara 23
Chicago 22
Moscow 18
Ho Chi Minh City 17
London 17
Pune 16
Warsaw 16
Hanoi 15
Washington 14
Ancona 13
Rome 13
Montreal 12
The Dalles 12
Atlanta 11
Brussels 11
Hefei 11
São Paulo 10
Boston 9
Denver 9
Johannesburg 9
Salt Lake City 9
Tokyo 8
Poplar 7
Shanghai 7
Urbisaglia 7
Amsterdam 6
Olomouc 6
Redmond 6
Shenzhen 6
Brasília 5
Brooklyn 5
Columbus 5
Elk Grove Village 5
Falls Church 5
Helsinki 5
Nuremberg 5
Orem 5
Rio de Janeiro 5
Stockholm 5
Tolentino 5
Wuhan 5
Zhengzhou 5
Arnold 4
Biên Hòa 4
Chennai 4
Guangzhou 4
Manchester 4
Mexico City 4
Qualiano 4
Baghdad 3
Belo Horizonte 3
Charlotte 3
Curitiba 3
Da Nang 3
Fermignano 3
Frankfurt am Main 3
Mumbai 3
Ninh Bình 3
Phoenix 3
Prescot 3
St Petersburg 3
Sterling 3
Tashkent 3
Wuxi 3
Araçatuba 2
Baku 2
Bauru 2
Bellante 2
Bolton 2
Calgary 2
Campo Verde 2
Caraguatatuba 2
Totale 2.817
Nome #
Are liver nested stromal epithelial tumors always low aggressive? 178
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 157
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 153
Optimal management of resected gastric cancer 150
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 146
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 139
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 138
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 135
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 132
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 131
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 129
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 125
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 109
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 107
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 106
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 105
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 104
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 103
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 102
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 102
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 101
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 99
Cancer patient perspective in the arena of COVID-19 pandemic 93
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 90
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 85
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 82
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 81
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 77
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 76
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 76
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 75
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 72
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 70
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 70
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 69
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 54
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 54
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 47
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 45
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 44
Totale 4.011
Categoria #
all - tutte 21.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.356


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021160 0 0 0 0 0 6 4 20 23 20 51 36
2021/2022276 3 26 5 6 17 34 13 15 48 16 36 57
2022/2023853 53 88 39 67 42 284 0 43 139 8 71 19
2023/2024405 67 9 28 32 48 127 2 8 0 17 5 62
2024/2025921 148 75 38 18 39 51 74 38 156 41 116 127
2025/20261.143 202 135 135 268 363 40 0 0 0 0 0 0
Totale 4.011